Phio Pharmaceuticals Corp. Price & Performance (PHIO)

Phio Pharmaceuticals has reported encouraging interim results from its ongoing Phase 1b trial of PH-762, an INTASYL siRNA therapy for skin cancers. Two patients achieved full tumor clearance while another showed a partial response, and no serious side effects were observed. The third trial cohort is fully enrolled, with study completion expected in Q3 2025.123

Phio Pharmaceuticals’ stock price soared by over 100% this week, driven by positive clinical trial data for PH-762 and growing speculation about new partnerships. The company’s strong cash position and lack of long-term debt have further bolstered investor confidence, despite recent volatility and ongoing operational challenges in the biotech sector.456

Phio Pharmaceuticals has implemented significant cost reduction measures, including downsizing facilities and reducing headcount, to focus resources on advancing its lead clinical program. Recent financings and warrant exercises have raised over $12 million, providing sufficient capital to complete ongoing trials and extend the company’s operational runway.278